Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Schulz

Showing results (461-470 of 473) with videos related to

Pageof 48
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 17, 1996
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptorsD W Schulz, R S Mansbach, J Sprouse, et al.
Annals of Neurology|August 12, 1999
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjectsP Parchi, A Giese, S Capellari, et al.
The International Journal of Occupational and Environmental Medicine|January 17, 2016
Mental Health Interventions in the Workplace and Work Outcomes: A Best-Evidence Synthesis of Systematic ReviewsS L Wagner, C Koehn, M I White, et al.
The International Journal of Occupational and Environmental Medicine|April 20, 2015
Job demand and control interventions: a stakeholder-centered best-evidence synthesis of systematic reviews on workplace disabilityK Williams-Whitt, M I White, S L Wagner, et al.
The International Journal of Occupational and Environmental Medicine|October 27, 2015
Social Support and Supervisory Quality Interventions in the Workplace: A Stakeholder-Centered Best-Evidence Synthesis of Systematic Reviews on Work OutcomesS L Wagner, M I White, I Z Schultz, et al.
Der Pathologe|March 1, 2021
[COVID-19 and the central and peripheral nervous system]N Ritschel, H Radbruch, C Herden, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2005
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisineJotham W Coe, Michael G Vetelino, Crystal G Bashore, et al.
Neuropharmacology|December 13, 2006
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidH Rollema, L K Chambers, J W Coe, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2005
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessationJotham W Coe, Paige R Brooks, Michael C Wirtz, et al.
Journal of Medicinal Chemistry|May 13, 2005
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessationJotham W Coe, Paige R Brooks, Michael G Vetelino, et al.
Pageof 48

Showing results (461-470 of 473) with videos related to

Sort By:
Pageof 48
Proceedings of the National Academy of Sciences of the United States of America|September 17, 1996
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptorsD W Schulz, R S Mansbach, J Sprouse, et al.
Annals of Neurology|August 12, 1999
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjectsP Parchi, A Giese, S Capellari, et al.
The International Journal of Occupational and Environmental Medicine|January 17, 2016
Mental Health Interventions in the Workplace and Work Outcomes: A Best-Evidence Synthesis of Systematic ReviewsS L Wagner, C Koehn, M I White, et al.
The International Journal of Occupational and Environmental Medicine|April 20, 2015
Job demand and control interventions: a stakeholder-centered best-evidence synthesis of systematic reviews on workplace disabilityK Williams-Whitt, M I White, S L Wagner, et al.
The International Journal of Occupational and Environmental Medicine|October 27, 2015
Social Support and Supervisory Quality Interventions in the Workplace: A Stakeholder-Centered Best-Evidence Synthesis of Systematic Reviews on Work OutcomesS L Wagner, M I White, I Z Schultz, et al.
Der Pathologe|March 1, 2021
[COVID-19 and the central and peripheral nervous system]N Ritschel, H Radbruch, C Herden, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2005
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisineJotham W Coe, Michael G Vetelino, Crystal G Bashore, et al.
Neuropharmacology|December 13, 2006
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidH Rollema, L K Chambers, J W Coe, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2005
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessationJotham W Coe, Paige R Brooks, Michael C Wirtz, et al.
Journal of Medicinal Chemistry|May 13, 2005
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessationJotham W Coe, Paige R Brooks, Michael G Vetelino, et al.
Pageof 48